SCHEMBL989583

SCHEMBL989583

O=S(=O)(NCCOc1ccc2c(c1)C(C1(c3ccc(Cl)cc3)CCC1)=NCC2)c1cccc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.41
SLC6A9 P48067 5/20 0.40
CYP3A4 P08684 1/20 0.40
HTR1A P08908 3/20 0.37
HTR7 P34969 3/20 0.37
DRD2 P14416 1/20 0.37
HTR6 P50406 1/20 0.37
F2 P00734 1/20 0.37
TRPV4 Q9HBA0 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NR1I2 O75469 1/20 0.35
HSD11B1 P28845 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
FBP1 P09467 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL989592 0.93 SLC6A9 (0.42) CCR1SLC6A9CYP3A4F2TRPV4
SCHEMBL989128 0.92 ALDH1A1 (0.43) CCR1SLC6A9CYP3A4F2MEN1
SCHEMBL990531 0.91 CCR1 (0.44) CCR1SLC6A9CYP3A4HTR7F2
SCHEMBL990369 0.91 SLC6A2 (0.42) SLC6A9CYP3A4F2NR1I2HSD11B1
SCHEMBL990093 0.89 MEN1 (0.48) CCR1SLC6A9CYP3A4F2MEN1
SCHEMBL988781 0.89 SLC6A9 (0.41) CCR1SLC6A9CYP3A4F2MEN1
SCHEMBL990394 0.87 SLC6A9 (0.40) CCR1SLC6A9CYP3A4TRPV4NR1I2
SCHEMBL989558 0.87 SLC6A9 (0.44) SLC6A9CYP3A4MEN1KMT2AMAOA
SCHEMBL1078429 0.86 SLC6A9 (0.50) CCR1SLC6A9CYP3A4HTR1AHTR7
SCHEMBL990434 0.86 SLC6A9 (0.48) CCR1SLC6A9CYP3A4HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957089-B2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG (DE) 2015-02-17 US disclosed
US-8653100-B2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2014-02-18 US disclosed
US-20130203749-A1 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2013-08-08 US disclosed
EP-2271625-B1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO KG (DE) 2012-09-12 EP disclosed
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott BmbH & Co. KG (DE) 2011-05-05 US disclosed
EP-2271625-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott GmbH & Co. KG (DE) 2011-01-12 EP disclosed
WO-2009121872-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO. KG (DE) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY GOLT1B, SLC10A1, SUGT1 CCR1 2958/4885SLC6A9 73/4885CYP3A4 328/4885
US-20130203749-A1 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy GOLT1B, SLC10A1, SUGT1 CCR1 2958/4885SLC6A9 73/4885CYP3A4 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.